Verena Briner - Novartis Insider

NVSN -- Mexico Stock  

MXN 1,591  12.80  0.80%

  Executive
Dr. Verena A. Briner, M.D., serves as NonExecutive Independent Member of the Board of Novartis AG since 2013. Dr. Briner is professor of internal medicine at the Universitaet Basel, Switzerland, and chief medical officer and head of the department of medicine at the Lucerne Cantonal Hospital in Switzerland. She is a member of several medical and ethical institutions and commissions, including the board of the Foundation for the Development of Internal Medicine in Europe, the senate of the Swiss Academy of Medical Sciences, and the supervisory group for personalized medicine of the Centre for Technology Assessment TASWISS. She also is a member and former president of the Swiss Society of Internal Medicine
Age: 64  Executive Since 2013      
41 61 324 1111  http://www.novartis.com
Briner graduated from the Universitaet Basel with an M.D. in 1978, and has a specialized degree in internal medicine and nephrology from the Swiss Medical Association. She has received several prestigious scholarships and scientific grants, including the President?s Grant of the Society of General Internal Medicine in 2011, and is an honorary fellow of the American College of Physicians, the European Federation of Internal Medicine, the Polish Association of Internal Medicine, and the Swiss Society of General Internal Medicine. She was chief medical officer and department head at Swiss hospital; former president of Swiss medical society; member of various medical and ethical institutions and commissions.

Management Efficiency

The company has return on total asset (ROA) of 4.65 % which means that it generated profit of $4.65 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.62 % meaning that it generated $11.62 on every $100 dollars invested by stockholders.
The company has accumulated 34.11 B in total debt with debt to equity ratio (D/E) of 47.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novartis AG has Current Ratio of 1.15 suggesting that it may not be capable to disburse its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Chris SuhMicrosoft Corporation
N/A
Pablo MejiaBanco de Chile
N/A
Maggie ODonnelFacebook
2015
Jose MBanco de Chile
N/A
Deborah CrawfordFacebook
2017
Oscar CastellonBanco de Chile
2008
Rodrigo MitriBanco de Chile
2017
Alejandro CantilloEcopetrol S A
2014
Magda CelyEcopetrol S A
2015
Zhenfei LiuAlibaba Group Holding Limited
2015
Nancy PaxtonApple
2016
Mauricio LetelierBanco de Chile
2005
Xiaofeng ShaoAlibaba Group Holding Limited
2012
Lei PengAlibaba Group Holding Limited
2014
Joaquin SilvaBanco de Chile
2017
Wenhong TongAlibaba Group Holding Limited
2017
Penhung TungAlibaba Group Holding Limited
2016
Ignacio AsisBanco de Chile
2014
Sergio AboitizBanco de Chile
2011
Timothy SteinertAlibaba Group Holding Limited
2007
Ricardo GomezEcopetrol S A
2016

Entity Summary

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG operates under Drug Manufacturers - Major classification in Mexico and traded on Mexico Stock Exchange. It employs 124000 people.Novartis AG (NVSN) is traded on Mexico Stock Exchange in Mexico. It is located in Lichtstrasse 35 and employs 124,000 people.

Novartis AG Leadership Team

Joerg Reinhardt, Chairman of the Board
Ton Buechner, Non-Executive Independent Director
Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee
Verena Briner, Non-Executive Independent Member of the Board
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Head of HR
Dimitri Azar, Member of the Board of Directors
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Enrico Vanni, Member of the Board of Directors
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Erwin Vanhaecke, Head Novartis Group Quality
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Michael Ball, CEO of Alcon, Member of the Executive Committee
Elizabeth Barrett, CEO, Novartis Oncology
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Member of the Board of Directors
Joseph Jimenez, CEO, Member of the Executive Committee
Samir Shah, Global Head Investor Relations
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Ann Fudge, Member of the Board of Directors
Srikant Datar, Member of the Board of Directors
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, CFO
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics

Stock Performance Indicators

Current Sentiment - NVSN

Novartis AG Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Search macroaxis.com